"" ALX Oncology Holdings Inc. saw a significant change in its leadership structure last week, with Shelly Wong, Senior Vice President of Finance and Chief Accounting Officer, selling $1,105 worth of company stock on August 17, 2026. Following this transaction, Wong directly owns 87,828 shares of ALX Oncology Holdings Inc. common stock.
The company has also announced the appointment of Scott Garland as the new Chairman of the Board of Directors, effective immediately. Garland succeeds co-founder Corey Goodman, who is stepping down after more than ten years with the company. Additionally, Michael Listgarten has been named as the new General Counsel. Garland has been a member of the ALX Oncology Board since November 2022 and brings over 30 years of experience in the biopharmaceutical industry.
These developments mark a notable shift in the company’s governance structure, as Garland and Listgarten bring industry expertise to the table. Wong, who has been with the company since its inception, will continue to play a key role in its financial and accounting functions.
Governance Structure Overhaul
The changes in leadership come as ALX Oncology Holdings Inc. continues to navigate the complexities of the biopharmaceutical industry. With Garland and Listgarten at the helm, the company is well-positioned to drive growth and innovation in the coming years.
Key Players
- Shelly Wong: Senior Vice President of Finance and Chief Accounting Officer
- Scott Garland: Chairman of the Board of Directors
- Corey Goodman: Former Chairman of the Board of Directors
- Michael Listgarten: General Counsel